Center Point Clinical Services announced this week its continuing partnership with ContraVir Pharmaceuticals that allows Center Point to provide its Clinical Trials Research Pharmacist (CTRP) solution to ContraVir as it continues the Phase III clinical trial of FV-100.
“ContraVir is taking every measure to make sure that the Phase 3 FV-100 study for shingles proceeds professionally and smoothly," ContraVir SVP of Drug Development Terri Matkovits said. "Crystal clear communication amongst all involved is essential to achieving these goals and robust outcomes. Securing strong channels of communication and patient engagement are CTRP specialties. Center Point’s capable, experienced and personable pharmacists prove their value daily. The trial patients are more compliant because of their expertise and personal attention and the trial team is better informed and in a timely manner. For these reasons, we are very pleased to be working with Center Point,”Shingles is a painful infection resulting from the chicken pox (varicella zoster) virus. After the initial chicken pox infection is over, the virus remains in nerve tissue in the body. The virus may reactivate and cause lesions, burning sensations and shooting pain. A shingles outbreak can last a month. While the shingles vaccine can reduce the number and severity of outbreaks, early treatment helps patients recover quickly and reduces the chance of complications.
The clinical trial is evaluating a once-daily dose of an oral antiviral medication FV-100. In addition to its antiviral activity, the medication is being evaluated for its ability to reduce the pain of shingles. Center Point's CTRP solution uses trained clinical pharmacists to link the study participants, trial team, sponsor and contract research organization (CRO). The CTRP solution helps patients maintain the medication regime while keeping the trial team informed as the trial progresses.